The life sciences industry continues to undergo significant transformation, with companies navigating through portfolio risks, pipeline challenges, public policy, and economic uncertainty. Our latest report reflects on mergers and acquisitions (M&A) trends and venture capital (VC) trends over the past year and provides considerations for biopharmaceutical companies heading into 2025. Discover the key insights below:
M&A activity has been subdued relative to 2023 with companies prioritizing growth and innovation
Acquirers continue to target pre-clinical therapeutics within oncology and central nervous systems (CNS) therapeutic areas
Cell and gene therapies (CGT) and anti-drug conjugates (ADCs) continue to be popular technology targets, with mRNA therapies gaining traction
VC dealmaking continues to remain steady, with 2024 deal volume tracking similarly to 2023
VC deals continue to concentrate around early-stage funding, reflecting a focus on novel innovative technologies
Biotech IPOs in 2024 to date have nearly doubled in volume relative to 2023, indicating acclimation to interest rates generally holding steady
Download the Report
Driving Value Through Complexity: Managing Multiple Carve-Outs in Private Equity
September 4, 2025
In an increasingly competitive M&A environment, PE firms are considering multiple and concurrent carve-outs as a fast way to unlock value from their assets. We share the five key areas of challenge when running concurrent carve-outs and how best to navigate them.
How Next-Generation Profitability Analysis Can Boost Your EBITDA
August 25, 2025
In today's competitive business landscape, traditional profitability analysis methods are falling short. Learn why the key to profitable growth is pursuing the right revenue, not just more revenue.
Green Shoots: Is Europe on the Cusp of an Infrastructure Investment Super-Cycle?
July 28, 2025
Infrastructure investment in Europe is gaining momentum, with the Q2 2025 GIIA survey showing a decisive shift in investor sentiment, signalling a potential supercycle as investors seek stability amid global uncertainties.
Decentralized vs. Centralized Procurement in the Nordic Construction Industry
July 24, 2025
Behind every purchasing decision lies a deeper debate: Should procurement be centralized or decentralized? While centralization offers cost savings, the decentralized approach is culturally ingrained. How can CEOs balance these strategies?
